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Abstract: In adult rats, the administration of lithium–pilocarpine (LiPilo) reproduces most clinical
and neuropathological features of human temporal lobe epilepsy (TLE). Carisbamate (CRS) possesses
the property of modifying epileptogenesis in this model. Indeed, about 50% of rats subjected to
LiPilo status epilepticus (SE) develop non-convulsive seizures (NCS) instead of motor seizures when
treated with CRS. However, the mechanisms underlying these effects remain unknown. The aim
of this study was to perform a proteomic analysis in the hippocampus of rats receiving LiPilo and
developing motor seizures or NCS following CRS treatment. Fifteen adult male Sprague–Dawley
rats were used. SE was induced by LiPilo injection. CRS treatment was initiated at 1 h and 9 h
after SE onset and maintained for 7 days, twice daily. Four groups were studied after video-EEG
control of the occurrence of motor seizures: a control group receiving saline (CT n = 3) and three
groups that underwent SE: rats treated with diazepam (DZP n = 4), rats treated with CRS displaying
NCS (CRS-NCS n = 4) or motor seizures (CRS-TLE n = 4). Proteomic analysis was conducted by
2D-SDS-PAGE. Twenty-four proteins were found altered. In the CRS-NCS group, proteins related
to glycolysis and ATP synthesis were down-regulated while proteins associated with pyruvate
catabolism were up-regulated. Moreover, among the other proteins differentially expressed, we
found proteins related to inflammatory processes, protein folding, tissue regeneration, response
to oxidative stress, gene expression, biogenesis of synaptic vesicles, signal transduction, axonal
transport, microtubule formation, cell survival, and neuronal plasticity. Our results suggest a global
reduction of glycolysis and cellular energy production that might affect brain excitability. In addition,
CRS seems to modulate proteins related to many other pathways that could significantly participate
in the epileptogenesis-modifying effect observed.
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1. Introduction
Recurrent spontaneous motor seizures are characteristic of temporal lobe epilepsy (TLE) [1].
They are associated with significant neuronal loss and morphological alterations which affect mainly
mesial temporal structures, such as hippocampal formation and amygdala [1–3]. The animal model
of TLE induced by pilocarpine (Pilo) reproduces the main clinical and pathophysiological features of
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human TLE, including mossy fiber sprouting, hippocampal sclerosis and gliosis [4,5]. In this model,
SE is followed by a latent period of 7–44 days until the appearance of spontaneous recurrent motor
seizures [4].
Approximately 30% of patients with MTLE present refractory seizures, despite numerous
antiepileptic drugs (AEDs) commercially available. Carisbamate (CRS, RWJ-333369; S-2-O-carbamoyl-1
-o-chlorophenyl-ethanol) is a new drug that possesses the property to dramatically modify
epileptogenesis in an experimental model of TLE [6–8]. These findings were observed when CRS
was applied starting 1 h after SE induced by lithium–pilocarpine (LiPilo). In brief, CRS induces
widespread neuroprotection and, most importantly, a disease- and insult-modifying effect in a
fraction of treated animals [8]. Some animals that underwent LiPilo SE developed non-convulsive
seizures (NCS) instead of the convulsive seizures commonly observed in this model. These NCS
recall absence seizures characterized by behavioral arrest accompanied by bilateral synchronous
spike-and-wave-discharges [9,10]. In addition, this sub-population of rats presents a cognitive profile
similar to that of control rats while rats with motor seizures are dramatically impaired [11,12]. However,
the mechanisms underlying these CRS-induced changes in the nature of LiPilo-induced epilepsy are
still unknown.
Previous studies looking at direct changes induced by this drug have shown that CRS may
inhibit voltage-gated sodium channels, thereby reducing action potential discharges and acting on
neuronal excitability [13]. It was also shown that CRS inhibits alpha-amino-3-hydroxy-5-methyl-4
-isoxazolepropionic acid (AMPA) and N-Methyl-D-aspartic acid (NMDA) excitatory post-synaptic
potentials, reducing glutamatergic transmission [14]. Finally, CRS affects also the serotonergic system
by increasing the tonic activation of somatodendritic 5-HT1A receptors, which leads to an inhibitory
action over hippocampal pyramidal cells [15]. In the same work, it was shown that CRS also acts on
noradrenergic and dopaminergic systems [15].
These mechanisms suggest that CRS can reduce neuronal excitability by affecting various
neurotransmitter systems and pathways synergistically. However, even if these results reveal potential
mechanisms of action of CRS, the effect of CRS over voltage-gated sodium channels, AMPA and
NMDA excitatory post-synaptic potentials as well as on serotonergic, noradrenergic and dopaminergic
systems do not explain the fact that in the chronic period of the LiPilo model about half the rats treated
with CRS do display NCS, with characteristics similar to absence seizures, instead of convulsive
seizures [8].
Herein, we explored changes occurring at two months after SE in the LiPilo model, by comparing
rats displaying convulsive seizures (treated or not with CRS), rats displaying NCS, and control rats.
We performed a proteomic study on the hippocampus of those rats to identify protein changes that
could help understanding why CRS is able to modify the expression of the disease. Our goal was to
perform a hippocampal proteome highlighting changes that might be the cause or consequence of this
disease-modifying feature. We hope that our study will help to identify new avenues of research for
future studies.
2. Results
Using two-dimensional separations of hippocampal homogenates, we could identify 24 proteins
differentially expressed among the four experimental groups (Figure 1 and Table 1). The identification
data was submitted to the PeptideAtlas (Id: PASS00899), a database that is part of the
ProteomeXchange Consortium.
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Figure 1. SDS-PAGE gel taken from a control (CT) rat showing the localization of all 24 spots of 
interest in a gel of the CT group (left upper quadrant). The other experimental groups studied were 
lithium–pilocarpine (LiPilo) rats treated with carisbamate (CRS) that subsequently displayed limbic 
seizures (CRS–TLE, left lower quadrant), LiPilo rats treated with CRS that subsequently displayed 
non-convulsive seizures (CRS-NCS, right upper quadrant), and LiPilo rats treated with diazepam 
(DZP, right lower quadrant). 
2.1. Proteomics 
The results revealed an increase of Dypsl2, Hspa8 and Gap43, a reduction of Gnai1, Pebp1, and 
Pdhb, in the DZP as compared to the CT group. There was also an up-regulation of Atp5d, Pdhb and 
Ldhb, and a down-regulation of Aco2, Adam17, Aldoa, Atp5a1, Ckmt1, Gapdh, Gnai1, Myh6, Pkm, 
Arhgdia, and Tubb2c in CRS-NCS as compared to CT rats. Furthermore, an increased level of Eno2 and 
Gap43, and decreased level of Ina, Snca, Gnai1, Ldhb, and Pebp1 were observed in CRS–TLE as 
compared to CT animals. The comparison between the CRS–NCS and DZP group showed up-
regulation of Snca, Atp5d, Eno4, Ldhb, Pebp1, and Pdhb, and down-regulation of Aco2, Adam17, 
Aldoa, Aldoc, Atp5a1, Ckmt1, Dpysl2, Gapdh, Hspa8, Myh6, Gap43, Pkm2, Arhgdia, and Tubb2c in 
CRS–EA rats. The CRS–TLE group showed up-regulation of Eno2, and Gap43, and down-regulation of 
Aldoc, Dpysl2, Hspa8, and Ldhb as compared to DZP. Up-regulation of Snca, Atp5d, Eno4, Ldhb, 
Pebp1, and Pdhb, and down-regulation of Aco2, Adam17, Eno2, Gapdh, Myh6, Gap43 Pkm2, and 
Arhgdia were recorded in CRS–NCS as compared to CRS–TLE rats. The identified spots are shown in 
Figure 1 representing a gel from a CT rat. 
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2.1. Proteomics
The results revealed an increase of Dypsl2, Hspa8 and Gap43, a reduction of Gnai1, Pebp1, and
Pdhb, in the DZP as compared to the CT group. There was also an up-regulation of Atp5d, Pdhb
and Ldhb, and a down-regulation of Aco2, Adam17, Aldoa, Atp5a1, Ckmt1, Gapdh, Gnai1, Myh6,
Pkm, Arhgdia, and Tubb2c in CRS-NCS as compared to CT rats. Furthermore, an increased level
of Eno2 and Gap43, and decreased level of Ina, Snca, Gnai1, Ldhb, and Pebp1 were observed in
CRS–TLE as compared to CT animals. The comparison between the CRS–NCS and DZP group showed
up-regulation of Snca, Atp5d, Eno4, Ldhb, Pebp1, and Pdhb, and down-regulation of Aco2, Adam17,
Aldoa, Aldoc, Atp5a1, Ckmt1, Dpysl2, Gapdh, Hspa8, Myh6, Gap43, Pkm2, Arhgdia, and Tubb2c in
CRS–EA rats. The CRS–TLE group h wed up-regulation of Eno2, a d Gap43, and down-regulation
of Aldoc, Dpysl2, Hspa8, and Ldhb as compared to DZP. Up-regul tion of Snca, Atp5d, Eno4, L hb,
Pebp1, and Pdhb, and down-regulation of Aco2, Adam17, Eno2, Gapdh, Myh6, Gap43 Pkm2, and
Arh dia w re recorded in CRS–N S as compared to CRS–TLE rats. The identified spots are shown in
Figure 1 representing a gel from a CT rat.
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Table 1. Proteins differentially expressed in the hippocampus of the four groups of rats.
Protein Gene UniProt ID
Mean of Optical Density
CT DZP CRS-TLE CRS-NCS
Aconitase Aco2 Q99798 4936 7904 6626 453 * # §
ADAM metallopeptidase domain 17 Adam17 Q9Z0F8 1378 1448 1380 911 * # §
Aldolase A Aldoa P05065 7537 9228 9117 679 * #
Aldolase C Aldoc P05063 2136 2659 1381 # 1951 #
Alpha internexin Ina P23565 8882 6997 5493 * 6656
Alpha synuclein Snca P37377 4141 1868 657 * 5590 # §
ATP synthase alpha subunit Atp5a1 P15999 9684 9106 5389 764 * #
ATP synthase delta subunit Atp5d P35434 2707 2437 2597 4079 * # §
Creatine kinase U-type Ckmt1 P25809 5151 5242 4467 3405 * #
Dihydropyrimidinase-like 2 Dpysl2 P47942 2079 6635 * 3166 # 2962 #
Enolase 4 Eno4 D3ZRT2 843 493 723 1168 # §
Enolase 2 Eno2 P07323 12,747 13,264 20,937 * # 12,009 §
Glyceraldehyde 3-phosphate dehydrogenase (Similar) RGD1565368 P04797 8984 9174 8824 3971 * # §
Glyceraldehyde 3-phosphate dehydrogenase Gapdh P04797 21,062 26,009 23,227 6032 * # §
Guanine nucleotide-binding protein G(i), alpha-1 subunit Gnai1 P10824 8054 2625 * 3925 * 2459 *
Heat shock cognate 71 kDa protein Hspa8 P63018 4763 13,475 * 7216 # 3475 #
lactate dehydrogenase chain-B Ldhb P42123 7183 7058 2502 * # 10,166 * # §
Myosin-6 Myh6 P02563 3063 3814 4148 1223 * # §
Neuromodulin Gap43 P07936 4202 10,646 * 20,957 * # 7264 # §
Phosphatidylethanolamine binding protein 1 Pebp1 P31044 9292 4951 * 4854 * 9429 # §
Pyruvate dehydrogenase E1 component Pdhb P49432 3930 2253 * 2647 7687 * # §
Pyruvate kinase M1/M2 Pkm2 P11980 7605 8491 7945 3497 * # §
Rho GDP dissociation inhibitor 1 Arhgdia Q5XI73 2987 2383 5142 767 * # §
Tubulin beta-2C chain Tubb2c P69897 127,231 142,920 * 98,280 * # 48,681 * #
Statistics: * (p < 0.05) = difference from CT group; # (p < 0.05) = difference from DZP group; § (p < 0.05) = difference from CRS–TLE group.
Pharmaceuticals 2017, 10, 67 5 of 19
2.2. Interactome
Using the GENEmania system we were able to identify 74 biological functions for our proteins of
interest, and 20 other proteins that have some kind of interaction with these proteins. Using the GO
ID’s generated by the GENEmania system and Cytoscape software; we could put all this information
together, which facilitated data analysis. Figure 2 shows an interaction map for all relevant comparisons.
In each case, 20 proteins with the higher interaction level were included. The comparison between
DZP vs. CT rats (Figure 2A) shows three up-regulated proteins and three down-regulated proteins
in DZP rats. Two up-regulated and 5 down-regulated proteins were included in Figure 2B for the
interaction map of the comparisons between CRS–TLE and CT group. Figure 2C shows the interaction
map including the three up-regulated and the 11 down-regulated proteins when comparing CRS–NCS
to CT rats. The comparison between CRS–TLE and DZP rats is shown in Figure 2D, which includes
two up-regulated and four down-regulated proteins. The interaction map for the six up-regulated
and fourteen down-regulated proteins found when comparing CRS-NCS to DZP rats is represented in
Figure 2E. Finally, the comparison between CRS-NCS and CRS-TLE rats is represented in the Figure 2F
and includes six up-regulated and eight down-regulated proteins.
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The proteins of interest revealed by the proteomic study include proteins of nine different 
protein classes (Figure 3A), six different cellular compartments (Figure 3B), six different molecular 
functions are related to our proteins of interest (Figure 3C) and nine biological functions as shown in 
Figure 3D.  
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The proteins of interest revealed by the proteomic study include proteins of nine different protein
classes (Figure 3A), six different cellular compartments (Figure 3B), six different molecular functions
are related to our proteins of interest (Figure 3C) and nine biological functions as shown in Figure 3D.
Pharmaceuticals 2017, 10, 67 6 of 19
Pharmaceuticals 2017, 10, x  6 of 20 
 
 
Figure 3. Schematic profile indicating the proportion (%) of the proteins of interest in each category: 
Protein class (A); cellular compartment (B); molecular function (C) and biological function (D). 
As can be observed in Figure 3A, the majority of identified proteins are lyases (35%) or 
membrane traffic proteins (17%) but there are also chaperones (10%), transporters (10%), cell junction 
proteins (8%), hydrolases (7%), enzyme modulators (5%), oxidoreductases (5%) and transferases 
(3%). Regarding the cellular compartment of identified proteins, 36% are located in the cell partition, 
22% in organelles, 14% are macromolecular complexes, 14% are membrane proteins, 7% are proteins 
located in synapses and 7% are cell junction proteins (Figure 3B). The interactome also revealed that 
identified proteins are mainly related to catalytic activity (36%) and transporter activity (22%), but 
we also found structural molecules (14%), regulator enzymes (14%), receptors (14%) and binding 
proteins (7%) (Figure 3C). Finally, in the list of biological functions related to the proteins of interest, 
35% are related to metabolic functions, 17% to cellular processes. About also 10% of proteins are 
classified according to localization, 10% are linked to biogenesis or component organization, 8% are 
developmental proteins, 7% are related to biological regulations, 5% are linked to multicellular 
organismal processes, 5% to response to stimulus and 3% are related to the immune system  
(Figure 3D).  
In addition to these global findings, we generated interactome crossing the groups, to know 
more details about protein classes, cell compartment, molecular and biological functions which play 
the proteins of interest (Table 2). The same strategy was used to know about the pathways in which 
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As can be observed in Figure 3A, the majority of identified proteins are lyases (35%) or membrane
traffic proteins (17%) but there are also chaperones (10%), transporters (10%), cell junction proteins (8%),
hydrolases (7%), enzyme modulators (5%), oxidoreductases (5%) and transferases (3%). Regarding the
cellular compartment of identified proteins, 36% are located in the cell partition, 22% in organelles,
14% are macromolecular complexes, 14% are membrane proteins, 7% are proteins located in synapses
and 7% are cell junction proteins (Figure 3B). The interactome also revealed that identified proteins are
mainly related to catalytic activity (36%) and transporter activity (22%), but we also found structural
molecules (14%), regulator enzymes (14%), receptors (14%) and binding proteins (7%) (Figure 3C).
Finally, in the list of biological functions related to the proteins of interest, 35% are related to metabolic
functions, 17% to cellular processes. About also 10% of proteins are classified according to localization,
10% are linked to biogenesis or component organization, 8% are developmental proteins, 7% are
related to biological regulations, 5% are linked to multicellular organismal processes, 5% to response
to stimulus and 3% are related to the immune system (Figure 3D).
In addition to these global findings, we generated interactome crossing the groups, to know more
details about protein classes, cell compartment, molecular and biological functions which play the
proteins of interest (Table 2). The same strategy was used to know about the pathways in which the
proteins of interest are involved in each group (Figure 4) and crossing the groups (Table 3).
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Table 2. Percentage of proteins related to protein class, cell compartment, molecular function and
biological function in the comparison between groups.
Protein Class CT vs.DZP
CT vs.
CRS-NCS
CT vs.
CRS-TLE
DZP vs.
CRS-NCS
DZP vs.
CRS-TLE
CRS-NCS vs.
CRS-TLE
transporter 6% 5%
hydrolase 6% 11% 33%
oxidoreductase 25% 18% 14% 16% 33% 21%
cell junction protein 6% 5% 7%
enzyme modulator 25% 18% 14% 11% 14%
lyase 25% 12% 14% 11% 33% 21%
transferase 25% 12% 11% 7%
nucleic acid binding 6% 5%
cytoskeletal protein 12% 14% 11% 7%
signaling molecule 6% 5% 7%
chaperone 14% 5% 7%
structural protein 14%
membrane traffic protein 14% 5% 7%
Cell Compartment CT vs.DZP
CT vs.
CRS-NCS
CT vs.
CRS-TLE
DZP vs.
CRS-NCS
DZP vs.
CRS-TLE
CRS-NCS vs.
CRS-TLE
synapse 17% 13% 8% 33% 14%
membrane 17% 17% 13% 8% 14%
macromolecular complex 17% 25% 13% 17%
cell part 33% 33% 38% 33% 33% 29%
organelle 17% 17% 25% 25% 33% 29%
cell junction 8% 8% 14%
Molecular Function CT vs.DZP
CT vs.
CRS-NCS
CT vs.
CRS-TLE
DZP vs.
CRS-NCS
DZP vs.
CRS-TLE
CRS-NCS vs.
CRS-TLE
binding 25% 20% 17% 17% 17%
receptor activity 5% 6%
structural molecule activity 10% 17% 11% 8%
signal transducer activity 25% 5% 17%
catalytic activity 50% 50% 50% 56% 100% 67%
transporter activity 10% 11% 8%
Biological Function CT vs.DZP
CT vs.
CRS-NCS
CT vs.
CRS-TLE
DZP vs.
CRS-NCS
DZP vs.
CRS-TLE
CRS-NCS vs.
CRS-TLE
response to stimulus 14% 5% 10%
immune system process 14% 5% 20%
developmental process 5% 30% 5% 7%
cellular process 14% 25% 24% 27%
multicellular organismal process 5% 5% 7%
Metabolic process 29% 35% 30% 33% 60% 40%
biological regulation 14% 5% 10% 20% 7%
cellular component organization
or biogenesis 14% 10% 10% 14% 13%
localization 10% 10% 14%
The interactome analysis also revealed that the proteins identified in the study, are mainly related
to glycolysis (14%) and to inflammation processes mediated by chemokine and cytokine signaling
(5%). We also found proteins associated to Huntington’s (5%) and Parkinson’s disease (5%) and also
associated to fructose and galactose metabolism (4.80%). In addition, minor changes (2%) were also
observed in several other pathways.
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Figure 4. Schematic representation of the path ays i e tifie i t e i teractome, indicating the
proportion (%) of proteins of interest related to each pathway.
Pharmaceuticals 2017, 10, 67 9 of 19
Table 3. Percentage of proteins involved in each specific pathway for each relevant group comparison.
Pathway CT vs.DZP
CT vs.
CRS-NCS
CT vs.
CRS-TLE
DZP vs.
CRS-NCS
DZP vs.
CRS-TLE
CRS-NCS vs.
CRS-TLE
ATP synthesis (P02721) 3% 4%
Metabotropic glutamate receptor group III
pathway (P00039) 5% 3% 5%
Apoptosis signaling pathway (P00006) 5% 4% 14%
Opioid proopiomelanocortin
pathway (P05917) 5% 3% 5%
Alzheimer disease-amyloid secretase
pathway (P00003) 4% 6%
Alzheimer disease-presenilin
pathway (P00004) 3% 4% 6%
Opioid prodynorphin pathway (P05916) 5% 3% 5%
Alzheimer disease-amyloid secretase
pathway (P00003) 3%
Opioid proenkephalin pathway (P05915) 5% 3% 5%
Enkephalin release (P05913) 5% 3% 5%
Inflammation mediated by chemokine and
cytokine signaling pathway (P00031) 5% 6% 5% 4% 6%
Dopamine receptor mediated signaling
pathway (P05912) 5% 3% 5%
Parkinson disease (P00049) 5% 5% 8% 14% 6%
EGF receptor signaling pathway (P00018) 5% 5% 4% 6%
Gonadotropin-releasing hormone receptor
pathway (P06664) 5% 3% 5%
PI3 kinase pathway (P00048) 5% 3% 5%
Cytoskeletal regulation by Rho
GTPase (P00016) 6% 8% 6%
Nicotine pharmacodynamics
pathway (P06587) 5% 3% 5%
Notch signaling pathway (P00045) 3% 4% 6%
Nicotinic acetylcholine receptor signaling
pathway (P00044) 3% 4% 6%
Muscarinic acetylcholine receptor 2 and 4
signaling pathway (P00043) 5% 3% 5%
Metabotropic glutamate receptor group II
pathway (P00040) 5% 3% 5%
Fructose galactose metabolism (P02744) 3% 8% 14%
Huntington disease (P00029) 6% 8% 6%
Pyruvate metabolism (P02772) 3% 4% 6%
Wnt signaling pathway (P00057) 3% 4%
Heterotrimeric G-protein signaling
pathway-Gi alpha and Gs alpha mediated
pathway (P00026)
5% 3% 5%
5HT1 type receptor mediated signaling
pathway (P04373) 5% 3% 5%
Glycolysis (P00024) 6% 5% 15% 29% 19%
GABA-B receptor II signaling (P05731) 5% 3% 5% 6%
Endogenous cannabinoid signaling (P05730) 5% 3% 5%
TCA cycle (P00051) 3% 4% 6%
FGF signaling pathway (P00021) 5% 5% 4% 6%
Axon guidance mediated by
semaphorins (P00007 4% 14%
Pyrimidine Metabolism (P02771) 4% 14%
2.3. Western Blot Confirmation
The Western blotting data pointed to an up-regulation of Pkm2 in the DZP vs. CT group (F(3, 20)
= 3.46; p = 0.035; BS p = 0.049—Figure 5A), and a higher level of Pdhb in CRS-NCS vs. DZP group
(F(3, 20) = 4.57; p = 0.013; BS p = 0.018—Figure 5B). However, no statistical intergroup difference was
observed in the level of Pebp1 (F(3, 20) = 3.28; p = 0.042; BS p = 0.051) and Dypsl2 (F(3, 20) = 2.94;
p = 0.057; BS p = 0.124) (Figure 5C,D).
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by behavioral arrest [10,16]. However, one needs to keep in mind that given that CRS treatment started
at 1 h after SE onset, both an insult- and disease-modifying effect might underlie the change in the
nature of the disease due to CRS treatment.
To highlight changes related to these insult- and disease-modifying effects, in the present
study, we analyzed the hippocampal proteome of all groups that underwent LiPilo SE compared to
saline-exposed animals. There is a growing number of studies using proteomic techniques to identify
protein changes and biomarkers for epilepsy [17–20]. Some of these studies have used hippocampal
tissue surgically removed from patients with refractory epileptic seizures [21,22]; others have used
tissue from animal models of TLE [23,24]. The proteomics based on two-dimensional electrophoresis
allowed us to get a visual map of the hippocampal proteome. It offers advantages over methods of
separation in which protein digestion is requested before separation [17].
In the present study, we identified the differential expression of proteins related to different
biological/molecular functions and pathways (see Figures 3 and 4). Briefly, these proteins are
mainly related to neuronal development and plasticity, glycolysis and energy production, and
neuronal excitability.
3.1. Neuronal Development and Plasticity
We observed alterations in proteins that are related to neuronal development and plasticity. This
was the case of Phosphatidylethanolamine-binding protein 1 (Pebp1), which was down-regulated in
both groups displaying motor seizures (DZP and CRS–TLE) when compared to CT and CRS–NCS
groups. Pebp1, an endogenous serine protease inhibitor, exerts inhibitory activity against several serine
proteases including thrombin, neuropsin, and chymotrypsin (not trypsin), tissue-type plasminogen
activator, and elastase [25]. Many processes are regulated by serine proteases, including tissue
homeostasis, neuronal growing [26], cell migration [27], cell death [28], and cell survival [29]. Therefore,
the “normalization” of Pebp1 protein observed in the CRS–NCS group could reflect improved tissue
homeostasis in these rats, while in epileptic rats its down-regulation could explain several deregulations
and dysfunctions.
The Dihydropyrimidinase-related protein 2 (Dpysl2) was up-regulated in DZP rats, while both
groups treated with CRS had a level similar to that of the CT group. Interestingly, this protein was
also found up-regulated in human hippocampal tissue from patients with TLE when compared to
control subjects [30]. Dpysl2 has an essential role in development and neuronal polarity, axon growth
and guidance, and in neuronal migration [31]. Thus, the increase in expression of this protein in
the hippocampus of DZP rats might be related to neurogenesis and synaptic reorganization that is
classically observed in TLE. On the other hand, its “normalization” in CRS-treated rats (both CRS–TLE
and CRS–NCS) suggests a reduction of tissue reorganization that can go as far as the prevention of
convulsive seizures in a sub-population of rats.
The protein Neuromodulin (Gap43) was found up-regulated in rats with convulsive seizures
(DZP and CRS–TLE) compared to CT and CRS–NCS. Gap43 has been associated to structural plasticity,
synaptic reorganization as well as neural development [32]. In addition, Gap43 seems to be linked with
mossy fiber sprouting in experimental models of epilepsy [33]. This protein is related to memory and
learning [34–36]. However, while moderate overexpression of Gap43 can enhance memory, excessive
overexpression may lead to memory dysfunction [34]. Our results show a similar level of Gap43 in
CRS–NCS compared to CT rats while it was increased in the DZP and CRS–TLE groups. Given the
properties of GAP43 in learning abilities, these data are in agreement with strongly degraded cognitive
abilities in DZP and CRS–TLE rats while cognitive performance of CRS–NCS remains remarkably
close to that of CT rats [11,12].
Finally, the Rho GDP-dissociation inhibitor 1 (Arhgdia or Rhogdi1) was reduced in CRS–NCS
compared to the three other groups. This protein is associated with neural development, axonal and
dendritic growth, anti-apoptosis effects, cell movement and negative regulation of cell adhesion [37,38].
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Moreover, Arhgdia has also been attributed a chaperone function, protecting multiple Rho proteins
from proteolytic degradation [37,39].
Altogether, these results suggests that CRS treatment exerts a modulatory role in Pebp1, Dpysl2,
Gap43 and Arhgdia, which could act on/reflect plasticity-related events commonly observed in
animals presenting convulsive seizures but not in animals displaying NCS.
3.2. Glycolysis and Energy Production
Interestingly, the present study revealed that almost one-third of altered proteins are related
to glycolysis and energy supply (Figure 6). The whole glycolytic process comprises 10 reactions
catalyzed by cytosolic enzymes during which a glucose molecule is oxidized to produce two molecules
of pyruvate (Figure 6). Therefore, the reduction of Aldoa, Gapdh, and Pkm2 suggests a global
reduction of the glycolytic process in rats treated with CRS and displaying NCS as compared to rats
with convulsive seizures. Carbohydrates and lipids are the main classes of molecules involved in
oxidative metabolism [40] and glycolysis is the main source of cellular energy, being essential for
brain and red blood cells [40]. In turn, pyruvate, the final product of glycolysis, can be metabolized
into acetyl-CoA by pyruvate dehydrogenase (PDH), in particular the subunit alpha E1 of pyruvate
dehydrogenase (Pdhb). This subunit is responsible for the activation/deactivation of the PDH
complex [41] and is the first link between glycolysis and the tricarboxylic acid cycle (TCA). On
the other hand, pyruvate can be converted into lactate by the action of L-lactate dehydrogenase (LDH).
These enzymes were up-regulated in the CRS–NCS group. However, given the global reduction of
expression of glycolysis-related proteins, the up-regulation of both enzymes, Pdhb and LDH observed
in the CRS–NCS group may be a compensatory mechanism allowing a sufficient flow of pyruvate into
the TCA.
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The acetyl-CoA, after entering the TCA, is converted into citrate by the action of the enzyme
Aco2. The redu tion of Aco2 in CRS–NCS rats suggests a possible reduction of NADH+, H+ and GTP
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levels. NADH+ is generated by glycolysis and TCA transfers of electrons to the cytochromes [42]. This
NADH+ is used in the synthesis of ATP from ADP + Pi, in a proportion of 3 ATP molecules for each
NADH+. We also found in the CRS–NCS group a reduction of Atp5a1, a subunit of mitochondrial
complex V at which level the synthesis of ATP from ADP takes place in the presence of a membrane
proton gradient [42].
Neuronal excitability is closely related to energy metabolism. First, the maintenance of neuronal
activity incurs a significant energy demand, which requires very active cellular metabolism [43]. In
addition, neurons in which the primary function is not primarily related to metabolism can also alter
their level of excitability in response to metabolic changes [43]. There is also some molecular link
between metabolism and neuronal excitability such as the nearby ATP-sensitive potassium (KATP)
channels that are activated by sub-membrane ATP consumption by ionic pumps [44,45]. A reduction of
the glycolytic pathway is also observed in the ketogenic diet, a treatment used to control drug-resistant
seizures [43].
3.3. Neuronal Excitability
In addition to these proteins related to glycolysis and cellular respiration, other proteins might
also have an impact on neuronal excitability. It is the case of the Heat shock cognate 71 kDa protein
(Hspa8), Alpha-synuclein (Snca) and Tubulin beta-2C chain (Tubb2c). The Hspa8, which we found
up-regulated in DZP rats but not in both groups treated with CRS (CRS–TLE and CRS–NCS) is a
chaperone protein that has an important role in heat-induced stress. This protein also interacts with
the intracellular CHL1 domain (a cell adhesion protein), being internalized and directed to synaptic
vesicles [46]. In fact, Hspa8 has a role in synaptic vesicle biogenesis and is responsible, together with
the auxilin protein, of the disassembly of the clathrin protein through an ATP-dependent reaction,
therefore controlling the release of vesicles [47]. The fact that Hspa8 is increased only in the DZP group
suggests an altered release of neurotransmitters such as GABA and glutamate, but also monoamines,
affecting the excitatory imbalance characteristic of epilepsy. In rats treated with CRS, whatever the
epileptic fate, TLE or NCS, the level of this protein was not affected.
The Snca, which was down-regulated in both groups displaying convulsive seizures (DZP and
CRS–TLE), but not in CRS–NCS rats, is an abundant protein in the brain, found mainly in presynaptic
terminals. Different neurodegenerative diseases show alterations in this protein [48,49]. This protein is
able to form pores on ion channels in the membrane with direct consequence on conductivity [50]. An
important role for this protein has been suggested in maintenance of the supply of synaptic vesicles in
presynaptic terminals [51]. Snca plays also a role in the regulation of dopamine transporters [52], and
dopamine biosynthesis by reducing the activity of tyrosine hydroxylase, a rate-limiting dopaminergic
enzyme [53]. Hence, alterations of Snca observed in rats displaying TLE could potentially affect the
dopaminergic system.
Finally, we found also an increased level of Tubulin beta-2C chain (Tubb2c) in the DZP group,
but levels were reduced in the CRS-TLE and CRS-NCS groups. The Tubb2c has an important role in
protein folding, a process in which a protein reaches its functional conformation. In addition, this
protein also acts in the axonal vesicle transport and Glut4 [54].
3.4. Pathways Observed in the CRS-NCS Group
Our interactome analysis revealed that the activation of pathways such pyruvate metabolism,
TCA cycle were observed only in comparisons made against the group CRS–NCS supporting the role
of proteins related to energy production and the outcome observed in this group. In addition, all
comparisons made against CRS–NCS also revealed the involvement with pathways such as cytoskeletal
regulation by Rho GTPase, Notch signaling, nicotinic acetylcholine receptor signaling.
In the Panther database, the cytoskeletal regulation by the Rho GTPase pathway implies that cell
moves and shape changes need rearrangements at the level of filaments that are regulated by Rho
GTPase (P00016—www.pantherdb.org). Interestingly, it was observed that rhoA knockout animals
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develop epileptic seizures during the first postnatal month [55,56], supporting the role of this protein
in convulsive seizures.
Notch is a trans-membrane receptor that mediates local cell–cell communication as well as in the
coordination of the signaling cascade (P00045—www.pantherdb.org). Traditionally, the Notch pathway
is associated to the regulation of neural stem cells; however, recent evidence suggests different roles for
Notch signaling in mature brain [57], and mainly an association with neuronal discharges. Noteworthy,
Notch signaling was found activated in a model of TLE and in human epileptogenic tissues [58].
The nicotinic acetylcholine receptor signaling also has a role in epilepsy. Indeed, it was identified
in a genetically transmissible form of epilepsy (frontal-lobe epilepsy) that is associated with a mutation
in the gene CHRNA4. This gene encodes a subunit of the nicotinic acetylcholine receptor. Interestingly,
polymorphisms at the level of this gene can disrupt the normal functioning of these receptors and may
provoke the imbalance between excitation and inhibition and cause seizures [59,60].
Thus, it appears that the hippocampus of CRS–NCS rats has undergone a wide array of molecular
changes compared to the DZP and CRS–TLE rats which might partly underlie the change in their
epileptic fate.
4. Materials and Methods
Animals: Thirty-nine adult male Sprague–Dawley rats (355 ± 31 g) provided by the University
of São Paulo were housed under controlled conditions (22 ± 1 ◦C, 12/12 h light/dark cycle, lights on
at 7:00 a.m.) with water and food ad libitum. The ethics research committee of the Federal University
of São Paulo (CEP N◦ 2072/11) approved all experiments. Efforts were made to minimize pain or
discomfort of animals. The experiments were performed following the principles outlined in the
ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines and the Basel declaration
(http://www.basel-declaration.org). The 3R concept (Replacement, Refinement and Reduction of
Animals in research) has been considered when planning the experiments.
SE Induction and CRS treatment: The protocol used were identical to our previous
studies [8,11,12]. In brief, rats were injected i.p. with 127 mg/kg lithium chloride. About 18 h
later they received methylscopolamine (1 mg/kg s.c., Sigma-Aldrich, St. Louis, MO, USA) in order
to limit the undesirable peripheral effects of pilocarpine. Thirty min later we induced the SE by
a administration of pilocarpine (25 mg/kg s.c., Sigma-Aldrich). The control group also received
lithium chloride but saline instead of pilocarpine. Then, 1 and 9 h after SE onset, rats were randomly
administered with diazepam (DZP, 2.5 and 1.25 mg/kg i.m., respectively, Roche, Meylan, France) or
CRS (90 mg/kg i.p., Johnson & Johnson Research & Development, L.L.C., Raritan, NJ, USA) dissolved
in 45% hydroxypropyl-β-cyclodextrin (Acros Organics, Geel, Belgium). DZP administered at low
doses enhanced survival of rats without modifying SE characteristics [61]. Over the following six days,
the CRS-treated groups received CRS injections (90 mg/kg, s.c.) twice daily. Untreated group received
saline instead of CRS. Rats were euthanized 2 months after SE induction.
Video monitoring: To avoid molecular alterations (such inflammation) due to electrode
implantation, we performed the monitoring for seizure identification only by using a video-recording
system. Starting one week after SE, video monitoring (24 h/7 days) was performed over a 2-month
period in order to assess seizure onset. Two groups of rats were obtained after CRS treatment, one
displaying convulsive seizures and the other one displaying non-convulsive seizures. We used the
Racine scale to classify convulsive seizures and rats presenting at least one stage III motor forelimb
clonus were used in the study [62]. As we showed previously, CRS-treated rats without convulsive
seizures and overt behavioral changes display absence-like spike-and-wave discharges (NCS) [8].
Experimental groups: Four experimental groups were used: (1) CT—a control group receiving
lithium chloride and saline; (2) DZP—rats that underwent SE and were treated with DZP 1 h after SE
onset; (3) CRS–TLE—rats that underwent SE, were treated with CRS and developed limbic seizures; and
(4) CRS–NCS—rats that underwent SE, were treated with CRS and developed non-convulsive seizures.
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Sample preparation: Two-dimensional SDS-PAGE was applied. Fifteen animals were used in this
experiment (3 CT; 4 CRS–NCS; 4 CRS–TLE and 4 DZP). Two months after SE, rats were euthanized by
decapitation and right and left hippocampi were dissected out, weighed and stored at −80 ◦C. Briefly,
hippocampal samples were homogenized in lysis buffer and the protein concentration was calculated
using the Bradford method [63]. After protein precipitation, an IPG strip with linear pH (3–10) was
used for the first dimension separation by isoelectric-focalization (IEF). After IEF, a polyacrylamide gel
(SDS-PAGE) was used for the second dimension separation. At the end of the run, gels were stained
with Comassie blue and then scanned by a densitometer, normalized to the background and analyzed
in the PDQuest 2D-gel software for quantification. Spots of interest were cut from the gel to proceed to
mass spectrometry identification. For more liability, we proceeded to the identification in duplicates
(each spot of interest was cut from two different experimental groups). After being cut, spots were
washed three times in a 100 mM solution containing 50% of acetonitrile and 50 mM of (NH4)2CO3.
After removing the supernatant, each spot was incubated with trypsin (200 ng of trypsin diluted in 50
mM (NH4)2CO3, 10% acetonitrile in H2O) overnight at 37 ◦C, for protein digestion. The addition of
formic acid 2% during 1 h was used to stop the digestion. Then, the supernatant was transferred to a
new vial that was used for identification in the mass spectrometer.
Mass spectrometry analyses: Peptides mixtures were separated by C18 (100 µm × 100 mm)
RP-nanoUPLC (nanoAcquity, Waters, Milford, MA, USA) coupled with a Q-Tof Premier mass
spectrometer (Waters) with nanoelectrospray source at a flow rate of 0.6 µL/min. The gradient
was 2–30% acetonitrile in 0.1% formic acid over 5 min for the digested proteins. The nanoelectrospray
voltage was set to 3.5 kV, a cone voltage of 30 V and the source temperature was 80 ◦C. The instrument
was operated in the ‘top three’ mode, in which one MS spectrum is acquired followed by MS/MS of the
top three most-intense peaks detected. After MS/MS fragmentation, the ion was placed on exclusion
list for 20 s and for the analysis of endogenous cleavage peptides, a real time exclusion was used. The
spectra were acquired using software MassLynx v.4.1 (Milford, MA, USA) and the raw data files were
converted to a peak list format (mgf) without summing the scans by the software Mascot Distiller
v.2.3.2.0, 2009 (Matrix Science Ltd., London, UK) allowing the label-free analysis. They were searched
against NCBInr_012014 (19922528 sequences; 6828478126 residues) with Rattus taxonomy selection
(61059 sequences) using Mascot engine v.2.3.01 (Matrix Science Ltd.), with carbamidomethylation as
fixed modification (+57 Da), oxidation of methionine, tryptophan and histidine (+16 Da), acetylation
of lysine (+42 Da), methylation of lysine and arginine (+14 Da) and phosphorylation of serine and
threonine (+80 Da) as variable modifications, one trypsin missed cleavage and a tolerance of 0.1 Da for
both precursor and fragment ions.
Proteome data analysis: The UniProtKB ID Mapping tool available on the UniProtKB web
site (www.uniprot.org) was used to obtain the ID numbers of the proteins of interest. The ExPASy
website (http://web.expasy.org/compute_pi/) was used to compute the theoretical isoelectric point
(Ip) and molecular weight (MW). We used the GENEmania system (http://www.genemania.org) to
identify biological functions in which the proteins of interest are involved. The QuickGo website
(http://www.ebi.ac.uk/QuickGO) and Panther (http://pantherdb.org/) were used to represent
schematically the biological functions identified and to localize the main biological functions.
Subsequently, the Cytoscape software was used to integrate this large amount of information,
facilitating the analysis work.
Western Blot: Twenty-four animals were used in this experiment (6/group). Western blot was
used to confirm the results obtained with 2-D electrophoresis proteomics. Hippocampal samples
(n = 6/group) were homogenized in lysis buffer and quantified using the Bradford method [63].
SDS-PAGE electrophoresis gels were used for protein separation. After the electrophoretic run,
protein bands were transferred by electro blotting to polyvinylidene fluoride (PVDF) membranes,
and incubated with primary antibodies (anti-PKM2, Anti-Dpysl2, Anti-Pdhb and Anti-Pebp1). In
the sequence, membranes were washed, incubated with the appropriated secondary antibody and
subjected to immunodetection procedure by chemiluminescence. Then membranes were washed
Pharmaceuticals 2017, 10, 67 16 of 19
and incubated with anti-β-actin. Bands were quantified by optical densitometry and the analysis
was performed using the ratio between the protein of interest and the corresponding loading control
(antibody raised against β-actin) for standardization of data.
Statistical analysis: The PDQuest software generated statistical difference of optical density in
the proteomic study. Western blotting data was analyzed by Analysis of Variance (ANOVA). The
post-hoc Tukey test was used when appropriate to identify statistical significance. Both, ANOVA and
post-hoc Tukey were performed with 10,000 bootstrap resampling. Statistical analysis was performed
in R version 3.0.2 [64].
5. Conclusions
Looking for long-term alterations in the hippocampal proteome, we observed a global reduction
of glycolysis- and respiration-related proteins, but also of proteins related to encapsulation and
neurotransmitter release (Hspa8 and Snca), neuronal excitability (Adam17), and axonal vesicle
transport (Tubb2c). We observed alterations in the TCA cycle, which may impact on the synthesis of
glutamate, GABA and aspartate [65]. In addition, we found alterations in proteins related to neuronal
development and plasticity (Dpysl2, Gap43 and Arhgdia). It is noteworthy that many proteins affected
are linked to glucose metabolism. Several studies have highlighted the anticonvulsant effect related
to alterations in glucose metabolism and the ketogenic diet has been the target of these studies. The
ketogenic diet changes several mechanisms related to cellular metabolism, mainly by deviating glucose
metabolism as the main energy source of the cell and activating anticonvulsive and neuroprotective
mechanisms [60]. On the other hand, it is not surprising that a reduction of brain reorganization, as seen
after CRS treatment in the LiPilo model [8]), will largely involve mechanisms linked to development
and plasticity. Further studies will be necessary to determine whether these altered proteins are caused
by the epileptic condition or whether they participate in the process of epileptogenesis.
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